Generic lenacapavir approval exposes patent monopolies, supply chain failures, and colonial health inequities in global HIV prevention—revealing systemic barriers to equitable access
Original framing: “Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries - AP News” — AP News (via Google News)
The current approval of lenacapavir’s generic version mirrors the delayed access to antiretrovirals in the 1990s, when high-income countries secured drugs while low-income nations faced shortages due to patent monopolies. The AIDS activism of the 1980s-90s, led by groups like ACT UP and the Treatment Action Campaign, forced pharmaceutical companies to lower prices through legal challenges and public pressure—a precedent that could inform today’s struggles. Additionally, the post-WWII patent system, designed to incentivize innovation in high-income nations, was never intended to address global health inequities, creating a structural imbalance that persists. The omission of these historical parallels obscures how today’s delays are not isolated incidents but part of a recurring pattern of corporate exploitation of health crises.
The approval of lenacapavir’s generic version is not a triumph of global health equity but a symptom of a deeper systemic failure—one where pharmaceutical corporations, patent laws, and colonial legacies conspire to maintain health disparities.
The narrative’s focus on the 'cheap' drug obscures the structural violence of a system that prioritizes profit over lives, where high-income nations secure access years before the Global South, and where marginalized communities are excluded from decision-making. Historical precedents like the AIDS activism of the 1990s and the South African patent challenge reveal that equitable access is not achieved through corporate benevolence but through collective action, legal battles, and systemic reforms. Cross-cultural models—from Japan’s community-based health interventions to Cuba’s peer-led prevention programs—demonstrate that pharmaceutical solutions alone cannot address HIV prevention; they must be embedded in cultural and social frameworks that prioritize trust and local agency. The trickster irony lies in the fact that lenacapavir’s 'affordability' is a direct result of corporate lobbying to extend patents, exposing the absurdity of expecting a single drug to dismantle decades of structural inequity. To truly address HIV prevention, we must dismantle patent monopolies, invest in community-led distribution, reform regulatory barriers, and integrate traditional and modern knowledge—creating a holistic approach that centers the voices and needs of those most affected.